Search the Newsreel

Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low - Time to Sell?

Cellebrite DI (NASDAQ:CLBT) shares recently fell to a new 52-week low of $10.55, despite previously closing at $15.25. While insider selling totaling $2.48 million occurred over the last three months, analysts maintain a "Moderate Buy" consensus with an average price target of $21.80. Institutional …

Cellebrite DI Q2 Earnings Call Highlights

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Cellebrite Appoints Shiven Ramji CEO as Company Sharpens Product Strategy

Cellebrite DI Ltd. has appointed Shiven Ramji as its new CEO, succeeding Thomas E. Hogan, to sharpen its product strategy with a focus on AI and new growth opportunities. Ramji, previously president of products and technology, will lead the company's expansion beyond digital forensics …

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control …

Cellebrite DI Ltd. (CLBT) Q2 Earnings and Revenues Miss Estimates

Cellebrite DI Ltd. (CLBT) reported Q2 earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12, and revenues of $131.14 million, which also fell short of expectations. The company's shares have declined by 15.4% year-to-date, contrasting with the S&P 500's gain, and …

Cellebrite (CLBT) CRO sells 411 shares to cover RSU tax obligations

Cellebrite DI Ltd.'s Global Chief Revenue Officer, Jewell Marcus, sold 411 ordinary shares on August 12, 2026, at a weighted average price of $16.0678 per share. This transaction was executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) granted …

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …

Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M

Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …

Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing

Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …

CELLEBRITE DI ($CLBT) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. ARR: Increased 21% to $508 million, missing the bottom end of guidance. Revenue: $131 million, up 16% year-over-year. Subscription Revenue: $119.5 million, up 16%, representing 91% of total revenue. Gross Profit: Increased 16% to $112 million, with a …

Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan

Cellebrite DI Ltd. announced that Shiven Ramji has been appointed Chief Executive Officer, succeeding Thomas E. Hogan, as part of a planned transition. The company also reported its second-quarter 2026 financial results, with total Annual Recurring Revenue (ARR) of $507.8 million, up 21% year-over-year, …

Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance

Cellebrite DI Ltd. (CLBT) reported Q2 EPS of $0.11, exceeding analyst estimates by $0.04, with revenue of $131.14 million. The company provided Q3 2026 revenue guidance of $145-148 million and full-year 2026 revenue guidance of $550-560 million, both slightly below consensus estimates.

Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk

Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary

Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …

Responsive Playbooks and the TIGO Inflection

This article provides an in-depth AI-generated analysis for Millicom International Cellular S.a. (NASDAQ: TIGO), highlighting neutral near and mid-term readings but a positive long-term bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …

Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?

Celldex Therapeutics (CLDX) recently reported wider losses and lower revenue for Q2 and H1 2026, yet its stock has seen significant recent gains. While the company trades at a 4.9x Price-to-Book multiple, suggesting it's overvalued compared to peers, a Discounted Cash Flow (DCF) model …

AbCellera Biologics prices oversubscribed $200M offering at $9.75/share

AbCellera Biologics (ABCL [https://seekingalpha.com/symbol/ABCL]) announced the pricing of its oversubscribed underwritten public offering [https://seekingalpha.com/pr/20617674-abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-common-shares] of 17.44M common shares at $9.75 per share. In lieu of common shares, AbCellera is also offering pre-funded warrants to purchase up to 3.08M common shares at $9.74999 per warrant …

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Chief Legal and Compliance Officer - Tryn Stimart President and Chief Executive Officer - Carl L. Hansen Chief Financial Officer - Andrew Booth Full Conference Call Transcript Operator: …

FuelCell Energy Inc. stock rises Wednesday, outperforms market

FuelCell Energy Inc. (FCEL) stock increased by 12.86% on Wednesday, closing at $21.67. This performance outpaced a mixed market session where the NASDAQ Composite rose, but the Dow Jones Industrial Average slightly declined. The rise ended a two-day losing streak for FuelCell Energy.

Why Is FuelCell Energy (NASDAQ:FCEL) In View as Markets Await the CPI Print?

FuelCell Energy (NASDAQ:FCEL) is drawing market attention as broad US equity markets await the consumer price index (CPI) report for July, with the stock seeing increased activity due to thin summer trading volumes. The article discusses FuelCell Energy's operations in stationary power generation, the …

FuelCell Energy (NASDAQ:FCEL) Trading Up 8% - Time to Buy?

FuelCell Energy (NASDAQ:FCEL) saw its shares rise 8% to $20.73, though trading volume was significantly lower than average. Analyst opinions are divided, with some upgrading the stock to "buy" with higher price targets, while others maintain "hold" or "sell" ratings, resulting in a consensus …

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's Why

Bloom Energy Jumps 13% as Nebius Picks Its Fuel Cells for AI Data Center, FuelCell Climbs 11%

Quick Read Nebius Group chose Bloom Energy fuel cells for its 300-megawatt AI data center, lifting BE 13% and FCEL 11% in sympathy. NVIDIA-backed Nebius surged 26% after its Q2 earnings call, while PLUG lagged with a 3% gain after leading the sector with …

Millicom International Cellular (TIGO) Stock forecasts

Millicom International Cellular (TIGO) offers wireless and fixed-line telecom services in Latin America. An analyst report from August 7, 2026, indicates that Millicom's margin gains continue to exceed expectations, with currency fluctuations also playing a role. The stock is currently priced at 96.47.

Cellectar Biosciences Q2 2026 Earnings Preview

* Cellectar Biosciences (CLRB [https://seekingalpha.com/symbol/CLRB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.52 [https://seekingalpha.com/symbol/CLRB/earnings/estimates] (+84.7% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 1 year, CLRB has …

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

AbCellera Biologics Inc. (NASDAQ:ABCL) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.83, notably boosted by Truist Financial's increased target of $30. The company's shares have rallied significantly following positive Phase 2 results for its experimental …

Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL)

Analysts have recently downgraded their revenue forecasts for AbCellera Biologics Inc. for 2024 and 2025, suggesting a more cautious outlook on the company's near-term growth prospects. Despite the revised estimates, the average price target for ABCL stock remains unchanged, implying that analysts see potential …

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

Omnicell (OMCL) shares have

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL)

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Quantinno Capital Management LP Has $1.92 Million Position in Omnicell, Inc. $OMCL

Quantinno Capital Management LP significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 390.2%, now holding 57,560 shares valued at $1.92 million. This move comes as institutional investors collectively own 97.7% of the company, and analysts maintain a "Moderate Buy" rating despite recent price …

FuelCell Energy, Inc. (NASDAQ:FCEL) Given Average Rating of "Hold" by Brokerages

FuelCell Energy (NASDAQ:FCEL) has received an average "Hold" rating from brokerages, with an average 12-month price target of $22.83. Several analysts have recently upgraded the stock, while an executive sold a significant portion of their shares. The company missed recent earnings and revenue estimates, …

First Trust Advisors LP Takes $758,000 Position in FuelCell Energy, Inc. $FCEL

First Trust Advisors LP has acquired a new position in FuelCell Energy, Inc. (NASDAQ:FCEL), purchasing 116,106 shares valued at approximately $758,000. Other institutional investors have also adjusted their holdings in FCEL, with significant buys from Legal & General Group Plc and Invesco Ltd. The …

Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX

Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has …